Iradimed (NASDAQ:IRMD) Issues Q3 2024 Earnings Guidance

Iradimed (NASDAQ:IRMD) issued an update on its third quarter 2024 earnings guidance on Thursday morning. The company provided EPS guidance of 0.380-0.410 for the period, compared to the consensus EPS estimate of 0.370. The company issued revenue guidance of $18.0 million-$18.2 million, compared to the consensus revenue estimate of $17.7 million. Iradimed also updated its FY 2024 guidance to 1.520-1.620 EPS.

Iradimed Stock Performance

Shares of IRMD stock traded down $0.90 during trading hours on Thursday, hitting $45.81. The company had a trading volume of 41,332 shares, compared to its average volume of 50,613. Iradimed has a 12 month low of $36.12 and a 12 month high of $50.93. The firm has a market capitalization of $579.95 million, a price-to-earnings ratio of 32.99 and a beta of 0.83. The firm’s fifty day moving average is $44.13 and its 200 day moving average is $43.58.

Iradimed (NASDAQ:IRMD) last announced its earnings results on Thursday, May 2nd. The medical equipment provider reported $0.32 EPS for the quarter, topping the consensus estimate of $0.31 by $0.01. The business had revenue of $17.60 million for the quarter, compared to the consensus estimate of $17.26 million. Iradimed had a return on equity of 24.63% and a net margin of 26.48%. On average, sell-side analysts expect that Iradimed will post 1.41 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Roth Mkm reissued a buy rating and issued a $65.00 target price on shares of Iradimed in a report on Monday, April 22nd. Roth Capital reiterated a buy rating on shares of Iradimed in a research report on Monday, April 22nd.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.